In addition, protein-based biomarkers, such as cytokines like TNF-α and Interleukin 6 (IL-6), have the potential to detect MASLD, suggesting that they can help identify inflammation-related Metabolic Dysfunction-Associated Steatohepatitis (MASH) and more advanced stages of fibrosis (68–71). The gene discussed is IL6; the disease is metabolic dysfunction-associated steatohepatitis.